Lumiphore advances its site-directed radiopharmaceutical development program with the receipt of an NSF SBIR Phase II Grant

BERKELEY, Calif., April 17, 2014 /PRNewswire-iReach/ -- Lumimphore Inc., a pharmaceutical leader in bifunctional chelator design, is developing in vivo radio-diagnostic imaging and site-directed radio-therapeutics, using its proprietary bifunctional radionuclide metal-chelation... Reported by PR Newswire 2 hours ago.